

Vision Statement

- » The VMS™ 3Dimensional technology monitors patients with heart disease.
- » The Ventripoint Medical System generates accurate measurements and a 3Dimensional model efficiently and inexpensively.
- » The market holds multi-billion dollar potential.

Company Overview

- » Ventripoint Diagnostics Ltd is a publicly traded company based out of Seattle.
- » The company trades on the TSX Venture under the ticker symbol VPT.
- » VentriPoint provides a patented and proprietary solution.
- » VPT delivers a 3-D model and analysis via a web based service to users in a matter of seconds.

Right Ventricle Measurement in Heart Disease

- » The majority of congenital heart anomalies primarily affect the right heart ventricle.
- » To assess the severity of heart disease progress, the size and shape of the heart is fundamental.
- » Accurate measurements of ventricular volume and function are essential to assessing cardiac overload and underlying congenital malformations.

Knowledge Based Reconstruction (KBR) with the VMS™

- » KBR employs the knowledge embodied in a database of ventricle shapes and their variations with human disease.
- » Users of the VMS™ identify key anatomical points from standard ultra sound images.
- » In a matter of seconds, using only these key points, KBR produces a 3-D image and computes volume and ejection fractions.

Market Facts

Shares Outstanding	102,627,375
Options	6,413,854
Warrants	25,835,350
Shares Fully Diluted	134,876,579
Insider Holdings	5%

Executive Team

Dr. George Adams
President & Chief Executive Officer

Amol Karnick
Vice President, Sales & Business Development

John Gebhart
Chief Financial Officer

Scott Ashley
Vice President, Research & Development

Florence H. Sheehan, M.D.
Co- Founder, Chief Scientist

Board of Directors

Dr. George Adams
Chief Executive Officer,
VentriPoint Diagnostics

Treuman P. Katz
President Emeritus, Seattle Children's
Hospital & Regional Medical Center

Danny Dalla-Longa
Co-founder, i3 Capital Partners


Brad Harlow
Managing Partner, B. Harlow & Associates,
LLC

Don Black
Former Chief Executive Officer of
Childrens Health Corporation of America

Hugh Cleland
Executive Vice President and Portfolio
Manager of Northern Rivers Funds

VentriPoint Medical System

- » The first cost-effective and accurate diagnostic tool for measuring right ventricle heart volume and function.
- » The VMS™ consists of a computer system, a tracking system sensor and transmitter, proprietary software.
- » Reconstruction, a 3-D model, volume and ejection fraction measurements are calculated in seconds.
- » The 3-D image is processed at VentriPoint's server and returned via the internet to the licensed user.



Competitive Landscape

- » VMS™ is consistent and highly precise.
- » VMS does not require additional imaging equipment.
- » VMS is economical.
- » VMS provides 3-dimensional models and highly accurate critical measurements for a fraction of the cost and time of an MRI.

VMS Market Applications and Regulatory

- » Initial market focus is congenital heart disease in paediatric and adults.
- » Pulmonary Hypertension and other heart disease markets to quickly follow (2012).
- » VMS™ approved in Canada (Health Canada), and Europe.
- » USA FDA application is in process, response expected by first quarter 2012.

Scientific Advisory Board

Michael Gatzoulis, M.D., Ph.D., F.A.C.C.,
Consultant Cardiologist in Cardiology and Pediatrics at the Royal Brompton Hospital, London.

Mark Lewin, M.D., Associate Professor of Pediatrics and co-Director of the Echocardiography Laboratory at Seattle Children's Hospital and Regional Medical Center.

David Sahn, M.D., Professor of Pediatrics at Oregon Health & Science University (OHSU) in Portland, Oregon.

Robyn J Barst, M.D., Dr. Barst founded the first pediatric and adult pulmonary hypertension center in 1982 at Columbia University and served as its director until 2008. She serves as a scientific advisor to pharmaceutical companies worldwide developing novel drugs for pulmonary hypertension.

Richard Krasuski, M.D., Director of Adult Congenital Heart Disease Services at Cleveland Clinic's Sydell and Arnold Miller Family Heart and Vascular Institute.

Collaborating Institutions

- » University of Washington
- » Children's Hospital and Regional Medical Center, Seattle Washington
- » Oregon Health & Science University
- » University Children's Hospital, Switzerland
- » Royal Brompton & Harefield NHS Trust, United Kingdom
- » University of Pennsylvania
- » Sophia Kindegeneeskunde BV, The Netherlands
- » Nationwide Children's Hospital, Columbus, Ohio
- » Alberta Children's Hospital, Calgary, AB
- » Children's Hospital & Medical Center, Omaha, Nebraska
- » St. Paul's Hospital, Vancouver, BC
- » Riley's Hospital, Indiana
- » Rikshospitalet in Oslo, Norway
- » Central Manchester University Hospitals NHS Foundation Trust, in Manchester UK

Investor Relations



The Howard Group Inc
Peter Weichler, Director

Telephone: 403.221.0915
Fax: 403.237.8387
Email: peter@howardgroupinc.com
www.info@howardgroupinc.com